World's Best Scientists 2026 revealed!
Award Badge
Medicine
Italy
2023

D-Index & Metrics

Medicine

D-Index
131
Citations
95110
World Ranking
2344
National Ranking
53

Research.com Recognitions

  • 2023 - Research.com Medicine in Italy Leader Award

Overview

Giovanni Scambia is affiliated with the Catholic University of the Sacred Heart in Italy. Their research contributions mainly focus on medicine, with a total of 1801 publications. Within this broad field, their work is concentrated in several subfields including obstetrics and gynecology, reproductive medicine, surgery, oncology, and epidemiology.

The scientist has extensively investigated topics related to cancer and reproductive health. Key areas of research include ovarian cancer diagnosis and treatment, endometrial and cervical cancer treatments, PARP inhibition in cancer therapy, uterine myomas and treatments, endometriosis research and treatment, cervical cancer and HPV research, and intraperitoneal and appendiceal malignancies.

Frequently publishing in leading journals, Giovanni Scambia's most productive publication venues include:

  • International Journal of Gynecological Cancer
  • Gynecologic Oncology
  • Cancers
  • European Journal of Surgical Oncology
  • Facts Views and Vision in ObGyn

Collaboration has played a significant role in their research, with frequent co-authors including:

  • Anna Fagotti
  • Francesco Fanfani
  • Domenica Lorusso
  • Giuseppe Vizzielli
  • Gabriella Ferrandina

The scientist has contributed to numerous peer-reviewed articles. Selected recent papers are:

  • "Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis," 2020, American Journal of Obstetrics & Gynecology MFM
  • "Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial," 2022, Journal of Clinical Oncology
  • "Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)," 2020, International Journal of Gynecological Cancer
  • "Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial," 2021, The Lancet Oncology
  • "Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study," 2021, The Lancet Oncology

Best Publications

  • Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Kathleen Moore;Nicoletta Colombo;Giovanni Scambia;Byoung Gie Kim

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski

  • Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial

    Pierluigi Benedetti Panici;Stefano Basile;Francesco Maneschi;Andrea Alberto Lissoni

  • Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

    Isabelle Ray-Coquard;Patricia Pautier;Sandro Pignata;David Pérol

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian

  • Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis.

    Daniele Di Mascio;Asma Khalil;Gabriele Saccone;Giuseppe Rizzo

  • Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.

    A. Bellacosa;D. De Feo;A. K. Godwin;D. W. Bell

  • Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study

    Giancarlo Agnelli;Gualberto Gussoni;Carlo Bianchini;Melina Verso

  • Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial

    Pierluigi Benedetti Panici;Angelo Maggioni;Neville Hacker;Fabio Landoni

  • Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer - Results from two randomised studies

    Thomas Hogberg;Mauro Signorelli;Carlos Freire de Oliveira;Roldano Fossati

  • Local-Regional Staging of Endometrial Carcinoma: Role of MR Imaging in Surgical Planning

    Riccardo Manfredi;Paoletta Mirk;Giulia Maresca;Pasquale A. Margariti

  • A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms

    Philipp Harter;Jalid Sehouli;Domenica Lorusso;Alexander Reuss

  • CLASS III BETA-TUBULIN OVEREXPRESSION IS A PROMINENT MECHANISM OF PACLITAXEL RESISTANCE IN OVARIAN CANCER PATIENTS

    Simona Mozzetti;Cristiano Ferlini;Paola Concolino;Flavia Filippetti

  • Semiquantitative RT-PCR analysis to assess the expression levels of multiple transcripts from the same sample.

    Maria Marone;Simona Mozzetti;Daniela De Ritis;Luca Pierelli

  • Role of microRNAs in drug-resistant ovarian cancer cells

    Antonio Sorrentino;Antonio Sorrentino;Chang Gong Liu;Antonio Addario;Cesare Peschle

  • A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study.

    Anna Fagotti;Gabriella Ferrandina;Francesco Fanfani;Alfredo Ercoli

  • Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.

    Anna Fagotti;Gabriella Ferrandina;Giuseppe Vizzielli;Francesco Fanfani

  • Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

    Sandro Pignata;Giovanni Scambia;Dionyssios Katsaros;Ciro Gallo

  • Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target.

    G. Scambia;F. O. Ranelletti;P. Benedetti Panici;R. De Vincenzo

  • Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer

    Andreas Du Bois;Anne Floquet;Jae Weon Kim;Jae Weon Kim;Joern Rau

Frequent Co-Authors

Gabriella Ferrandina
Gabriella Ferrandina Catholic University of the Sacred Heart
Salvatore Mancuso
Salvatore Mancuso Catholic University of the Sacred Heart
Domenica Lorusso
Domenica Lorusso Catholic University of the Sacred Heart
Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Sandro Pignata
Sandro Pignata National Cancer Institute
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Fabio Ghezzi
Fabio Ghezzi University of Insubria
Francesco Cosentino
Francesco Cosentino Karolinska University Hospital
Pierluigi Benedetti Panici
Pierluigi Benedetti Panici Sapienza University of Rome
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a variety of online healthcare degrees and specialized career pathways. For students who prefer flexible learning or require cost-efficient options, online programs have become more accessible and diverse.

One fast-growing field is medical administration. Taking medical billing and coding cost into consideration, online courses can be a practical entry point into healthcare with manageable fees and job-ready skills.

Aspiring nurses can discover several affordable nursing programs online, making it easier to earn a degree without a heavy financial burden. Those looking to advance in their careers may consider the cheapest nurse practitioner programs, combining affordability with qualification development.

For those aiming for academic or leadership roles in healthcare, pursuing an online phd nursing can offer flexibility and cost savings. These pathways not only expand career options but also help meet the growing demand for healthcare professionals in the USA.

Best Scientists Citing Giovanni Scambia

Trending Scientists

Recently Published Articles